These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21426101)

  • 1. Low-molecular-weight MK2 inhibitors: a tough nut to crack!
    Schlapbach A; Huppertz C
    Future Med Chem; 2009 Oct; 1(7):1243-57. PubMed ID: 21426101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
    Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
    Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2).
    Olsson H; Sjö P; Ersoy O; Kristoffersson A; Larsson J; Nordén B
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4738-40. PubMed ID: 20643547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro.
    Hendriks BS; Seidl KM; Chabot JR
    BMC Syst Biol; 2010 Mar; 4():23. PubMed ID: 20230629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II.
    Revesz L; Schlapbach A; Aichholz R; Dawson J; Feifel R; Hawtin S; Littlewood-Evans A; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4719-23. PubMed ID: 20591669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based lead identification of ATP-competitive MK2 inhibitors.
    Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.
    Schlapbach A; Feifel R; Hawtin S; Heng R; Koch G; Moebitz H; Revesz L; Scheufler C; Velcicky J; Waelchli R; Huppertz C
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6142-6. PubMed ID: 18945615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-inflammatory cytokine release in keratinocytes is mediated through the MAPK signal-integrating kinases.
    Kjellerup RB; Kragballe K; Iversen L; Johansen C
    Exp Dermatol; 2008 Jun; 17(6):498-504. PubMed ID: 18081851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800.
    Fujino A; Fukushima K; Namiki N; Kosugi T; Takimoto-Kamimura M
    Acta Crystallogr D Biol Crystallogr; 2010 Jan; 66(Pt 1):80-7. PubMed ID: 20057052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-penetrating peptides can confer biological function: regulation of inflammatory cytokines in human monocytes by MK2 inhibitor peptides.
    Brugnano JL; Chan BK; Seal BL; Panitch A
    J Control Release; 2011 Oct; 155(2):128-33. PubMed ID: 21600941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
    Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK
    J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of MK2 shows promise for preventing postoperative ileus in mice.
    Liu X; Wu T; Chi P
    J Surg Res; 2013 Nov; 185(1):102-12. PubMed ID: 23764316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct role of MAPKAPK-2 in the regulation of TNF gene expression by Toll-like receptor 7 and 9 ligands.
    Thuraisingam T; Xu YZ; Moisan J; Lachance C; Garnon J; Di Marco S; Gaestel M; Radzioch D
    Mol Immunol; 2007 Jul; 44(14):3482-91. PubMed ID: 17485113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element.
    Hitti E; Iakovleva T; Brook M; Deppenmeier S; Gruber AD; Radzioch D; Clark AR; Blackshear PJ; Kotlyarov A; Gaestel M
    Mol Cell Biol; 2006 Mar; 26(6):2399-407. PubMed ID: 16508014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.
    Venkatesan AM; Dehnhardt CM; Chen Z; Santos ED; Dos Santos O; Bursavich M; Gilbert AM; Ellingboe JW; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham R; Mansour TS
    Bioorg Med Chem Lett; 2010 Jan; 20(2):653-6. PubMed ID: 19954970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogen-activated protein kinase inhibitors.
    Williams RG; Kandasamy R; Nickischer D; Trask OJ; Laethem C; Johnston PA; Johnston PA
    Methods Enzymol; 2006; 414():364-89. PubMed ID: 17110203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRIF signaling stimulates translation of TNF-alpha mRNA via prolonged activation of MK2.
    Gais P; Tiedje C; Altmayr F; Gaestel M; Weighardt H; Holzmann B
    J Immunol; 2010 May; 184(10):5842-8. PubMed ID: 20375303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapeutic Potential of Mitogen-Activated Protein Kinase Activated Protein Kinase 2 (MK2) in Chronic Airway Inflammatory Disorders.
    Singh RK; Najmi AK
    Curr Drug Targets; 2019; 20(4):367-379. PubMed ID: 30112991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series.
    Oubrie A; Kaptein A; de Zwart E; Hoogenboom N; Goorden R; van de Kar B; van Hoek M; de Kimpe V; van der Heijden R; Borsboom J; Kazemier B; de Roos J; Scheffers M; Lommerse J; Schultz-Fademrecht C; Barf T
    Bioorg Med Chem Lett; 2012 Jan; 22(1):613-8. PubMed ID: 22119462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.